- Home
- KRG vs ALKS Comparison
KRG vs ALKS Comparison
Compare KRG & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRG
- ALKS
- Stock Information
- Founded
- KRG 1971
- ALKS 1987
- Country
- KRG United States
- ALKS Ireland
- Employees
- KRG N/A
- ALKS N/A
- Industry
- KRG Real Estate Investment Trusts
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- KRG Real Estate
- ALKS Health Care
- Exchange
- KRG Nasdaq
- ALKS Nasdaq
- Market Cap
- KRG 5.0B
- ALKS 4.8B
- IPO Year
- KRG 2004
- ALKS 1991
- Fundamental
- Price
- KRG $22.03
- ALKS $30.56
- Analyst Decision
- KRG Buy
- ALKS Buy
- Analyst Count
- KRG 7
- ALKS 13
- Target Price
- KRG $27.71
- ALKS $38.85
- AVG Volume (30 Days)
- KRG 1.7M
- ALKS 1.6M
- Earning Date
- KRG 07-29-2025
- ALKS 07-23-2025
- Dividend Yield
- KRG 4.88%
- ALKS N/A
- EPS Growth
- KRG N/A
- ALKS N/A
- EPS
- KRG 0.06
- ALKS 2.09
- Revenue
- KRG $856,165,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- KRG $2.10
- ALKS N/A
- Revenue Next Year
- KRG $3.65
- ALKS $4.11
- P/E Ratio
- KRG $364.20
- ALKS $14.52
- Revenue Growth
- KRG 3.94
- ALKS N/A
- 52 Week Low
- KRG $18.52
- ALKS $22.90
- 52 Week High
- KRG $28.24
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- KRG 46.54
- ALKS 54.70
- Support Level
- KRG $21.19
- ALKS $29.70
- Resistance Level
- KRG $23.18
- ALKS $31.76
- Average True Range (ATR)
- KRG 0.38
- ALKS 0.73
- MACD
- KRG -0.08
- ALKS -0.01
- Stochastic Oscillator
- KRG 29.62
- ALKS 66.02
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.